Company: SHPH
Filing Date: 2025-04-21
Form Type: DEFR14A
Source: 0001641172-25-005474
Chunk: 2

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-21
Form: DEFR14A
Chunk 2
---
, to determine an optimal dose for use in glioblastoma patients in combination with RT. After the
optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point
demonstrating increased survival as compared to historical controls.

This clinical trial is critical to the broader radiation therapy industry as we look to leverage radiation sensitizers to increase
cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to continued
trial execution as we aim to improve the lives of millions of patients impacted by cancer and to bring hope to patients and families
around the world.

ADVANCEMENT OF A ROBUST DEVELOPMENT PORTFOLIO

Our primary focus is
on our lead therapeutic Ropidoxuridine program. However, it remains important to understand the depth of development stage assets across
both cancer Therapeutics and Diagnostics.

THERAPEUTICS

Within Therapeutics,
after Ropidoxuridine, the second priority has been focused on our HDAC6 selective inhibitor SP-2-225. During the past year, we have contracted
with Dr. Alejandro Villagra’s laboratory at Georgetown University to perform in vivo studies of HDAC6 inhibition in 4T1 syngeneic
mouse breast cancers. Tumor growth delay has
been observed, and validation experiments have
been completed. SP-2-225 is ready for IND-enabling studies followed by Phase I clinical testing.

Development of other preclinical assets, including our next generation radiation sensitizer formulation of Ropidoxuridine / Tipiracil
and our Class I selective HDAC inhibitor for ER+ breast cancer, will be prioritized as funds become available. In addition, we plan to submit applications for NIH funding and seek
collaborations or joint ventures to support further development of selected preclinical assets.

DIAGNOSTICS

Our Shuttle Diagnostics
subsidiary aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients. The PC-Rad test was developed for predicting outcomes following radiation
therapy for localized prostate cancer and the PSMA-B ligand is a theranostic molecules offering diagnosis and therapeutics capability
for metastatic prostate cancer.

The intellectual property
underlying the PC-Rad Test predictive biomarker
technology was developed by a collaboration of Shuttle Pharma and Georgetown University scientists through analytical validation and
is ready for clinical validation to seek FDA approval as a medical